Kymera Therapeutics (KYMR) Receivables (2020 - 2025)
Historic Receivables for Kymera Therapeutics (KYMR) over the last 6 years, with Q2 2025 value amounting to $40.0 million.
- Kymera Therapeutics' Receivables rose 224741.78% to $40.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $40.0 million, marking a year-over-year increase of 224741.78%. This contributed to the annual value of $900000.0 for FY2024, which is 9520.31% down from last year.
- Per Kymera Therapeutics' latest filing, its Receivables stood at $40.0 million for Q2 2025, which was up 224741.78% from $947000.0 recorded in Q4 2024.
- In the past 5 years, Kymera Therapeutics' Receivables registered a high of $40.0 million during Q2 2025, and its lowest value of $947000.0 during Q4 2024.
- In the last 5 years, Kymera Therapeutics' Receivables had a median value of $1.9 million in 2021 and averaged $8.6 million.
- As far as peak fluctuations go, Kymera Therapeutics' Receivables tumbled by 9495.26% in 2024, and later soared by 224741.78% in 2025.
- Over the past 5 years, Kymera Therapeutics' Receivables (Quarter) stood at $1.8 million in 2021, then soared by 42.69% to $2.5 million in 2022, then surged by 639.53% to $18.8 million in 2023, then plummeted by 94.95% to $947000.0 in 2024, then skyrocketed by 4123.86% to $40.0 million in 2025.
- Its Receivables was $40.0 million in Q2 2025, compared to $947000.0 in Q4 2024 and $1.3 million in Q3 2024.